Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, Bernthal NM, López Pousa A, Razak AA, Italiano A, Ahmed M, Le Cesne A, Tinoco G, Boye K, Martín-Broto J, Palmerini E, Tafuto S, Pratap S, Powers BC, Reichardt P, Casado Herráez A, Rutkowski P, Tait C, Zarins F, Harrow B, Sharma MG, Ruiz-Soto R, Sherman ML, Blay JY, Tap WD, MOTION investigators

Open source

DOI: 10.1016/s0140-6736(24)00885-7
Published: 2024 Jun 22
Container: Lancet (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-24-00885-7,
  title = {Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.},
  author = {Gelderblom H and Bhadri V and Stacchiotti S and Bauer S and Wagner AJ and van de Sande M and Bernthal NM and López Pousa A and Razak AA and Italiano A and Ahmed M and Le Cesne A and Tinoco G and Boye K and Martín-Broto J and Palmerini E and Tafuto S and Pratap S and Powers BC and Reichardt P and Casado Herráez A and Rutkowski P and Tait C and Zarins F and Harrow B and Sharma MG and Ruiz-Soto R and Sherman ML and Blay JY and Tap WD and MOTION investigators},
  year = {2024},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(24)00885-7},
  url = {https://doi.org/10.1016/s0140-6736(24)00885-7}
}

RIS

TY  - JOUR
TI  - Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
AU  - Gelderblom H
AU  - Bhadri V
AU  - Stacchiotti S
AU  - Bauer S
AU  - Wagner AJ
AU  - van de Sande M
AU  - Bernthal NM
AU  - López Pousa A
AU  - Razak AA
AU  - Italiano A
AU  - Ahmed M
AU  - Le Cesne A
AU  - Tinoco G
AU  - Boye K
AU  - Martín-Broto J
AU  - Palmerini E
AU  - Tafuto S
AU  - Pratap S
AU  - Powers BC
AU  - Reichardt P
AU  - Casado Herráez A
AU  - Rutkowski P
AU  - Tait C
AU  - Zarins F
AU  - Harrow B
AU  - Sharma MG
AU  - Ruiz-Soto R
AU  - Sherman ML
AU  - Blay JY
AU  - Tap WD
AU  - MOTION investigators
PY  - 2024
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(24)00885-7
UR  - https://doi.org/10.1016/s0140-6736(24)00885-7
ER  -

APA

H, G., V, B., S, S., S, B., AJ, W., M, V. D. S., NM, B., A, L. P., AA, R., A, I., M, A., A, L. C., G, T., K, B., J, M., E, P., S, T., S, P., BC, P., P, R., A, C. H., P, R., C, T., F, Z., B, H., MG, S., R, R., ML, S., JY, B., WD, T., & investigators, M. (2024). Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(24)00885-7

Source records

pubmed · retrieved 2026-09-26T13:53:36.117Z